Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.42
11.34
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Maravai LifeSciences Holdings Inc
Maravai LifeSciences Holdings Inc
Accrued Liabilities
Maravai LifeSciences Holdings Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
|
Accrued Liabilities
$56.6m
|
CAGR 3-Years
25%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Accrued Liabilities
$5.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Danaher Corp
NYSE:DHR
|
Accrued Liabilities
$2.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Accrued Liabilities
$364.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Accrued Liabilities
$573m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Maravai LifeSciences Holdings Inc
Glance View
Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 470 full-time employees. The company went IPO on 2020-11-20. The firm provides products that enables the development of drug therapies, diagnostics, vaccines and support research on human diseases. The firm's segments include Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The company also provides research products for labeling and detecting proteins in cells and tissue samples. Its products include CleanCap, messenger ribonucleic acid (mRNA) and oligonucleotide. The Biologics Safety Testing focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing spectrum. The firm provides ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets.
See Also
What is Maravai LifeSciences Holdings Inc's Accrued Liabilities?
Accrued Liabilities
56.6m
USD
Based on the financial report for Dec 31, 2023, Maravai LifeSciences Holdings Inc's Accrued Liabilities amounts to 56.6m USD.
What is Maravai LifeSciences Holdings Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
39%
Over the last year, the Accrued Liabilities growth was 12%. The average annual Accrued Liabilities growth rates for Maravai LifeSciences Holdings Inc have been 25% over the past three years , 39% over the past five years .
You don't have any saved screeners yet
